BIOPOR Bioporto A/S

Peter Mørch Eriksen resigns as CEO of BioPorto A/S

Peter Mørch Eriksen resigns as CEO of BioPorto A/S

May 5, 2021

Announcement no. 10

Peter Mørch Eriksen resigns as CEO of BioPorto A/S

After having led BioPorto as CEO for almost 8 years, BioPorto’s Chief Executive Officer, is resigning his position as CEO of the Company. Peter will continue to support the Company until end of January 2022, and will retain his position as CEO until his successor has been found.

Peter Mørch Eriksen says: “It is, and has been, a privilege to be CEO of BioPorto, and I look forward to continue to support the Company’s ongoing projects, including the clinical studies and expected submission this summer of a De Novo application to the FDA for pediatric use of The NGAL Test™. Considering the important milestones ahead for BioPorto, I find this to be the right time to find my successor who can lead the Company into its next phase.”

Thomas Magnussen, Chairman of the Board of Directors, says: “I wish to thank Peter for his tremendous efforts for the Company over many years. I and the rest of the organization look forward to continue working with Peter over the coming months, as we proceed to identify and appoint his successor and further advance the ongoing transition of the Company to the North American market.”

For further information, please contact:

Thomas Magnussen, Chairman of the Board

Telephone , e-mail:

About BioPorto

BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR].

Attachment



EN
05/05/2021

Underlying

BIOPORBioporto A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bioporto A/S

 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

BioPorto sponsorerer konferencer om pædiatrisk intensiv behandling med...

BioPorto sponsorerer konferencer om pædiatrisk intensiv behandling med præsentation af nye videnskabelige data om NGAL 26. september, 2025Meddelelse BioPorto sponsorerer konferencer om pædiatrisk intensiv behandling med præsentation af nye videnskabelige data om NGAL KØBENHAVN, DANMARK og BOSTON, MA, USA, 26. september – BioPorto A/S (“BioPorto” eller “Selskabet”) (CPH:BIOPOR), annoncerer sin støtte til konferencer med fokus på pædiatriske organtransplantationer og intensiv behandling indenfor nefrologi. Kliniske forskere præsenterer posters, resuméer og nye publikationer, hvor NGAL anven...

September 26, 2025 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL...

BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented September 26, 2025News Release BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented COPENHAGEN, DENMARK and BOSTON, MA, USA, September 26 – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), is pleased to support conferences focused on pediatric solid organ transplants and critical care nephrology. Clinical researchers present posters, abstracts and new publications using NGAL in their patients, leading to better identification for risk of Acut...

September 26, 2025 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

US News & World Report-webinaret “New Frontiers in Kidney Care” fremhæ...

US News & World Report-webinaret “New Frontiers in Kidney Care” fremhæver NGAL-biomarkøren 11. september, 2025Meddelelse US News & World Report-webinaret “New Frontiers in Kidney Care” fremhæver NGAL-biomarkøren KØBENHAVN, DANMARK og BOSTON, MA, USA, 11. september – BioPorto A/S (BioPorto eller Selskabet) (CPH:BIOPOR) annoncerer det kommende virtuelle arrangement fra US News & World Report: “New Frontiers in Kidney Care”, som vil fokusere på akut og kronisk nyresygdom globalt samt de tiltag, der kan sikre de bedst mulige behandlingsresultater inden for nyresundhed. Webinaret afholdes tors...

September 11, 2025 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

US News & World Report Webinar “New Frontiers in Kidney Care” features...

US News & World Report Webinar “New Frontiers in Kidney Care” features NGAL biomarker September 11, 2025News Release US News & World Report Webinar “New Frontiers in Kidney Care” features NGAL biomarker COPENHAGEN, DENMARK and BOSTON, MA, USA, September 11 – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), is pleased to announce the upcoming US News & World Report live virtual event "New Frontiers in Kidney Care” which will focus on acute and chronic kidney disease globally and actions that can be taken to ensure best possible outcomes in kidney care. The program will run live on ...

September 11, 2025 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

Tildeling af Warrants

Tildeling af Warrants 1. september 2025 Meddelelse nr. 20                                                                          Tildeling af Warrants København, Danmark, den 1. september 2025 (GLOBE NEWSWIRE) – Bestyrelsen for BioPorto A/S ("BioPorto" eller "Selskabet") (CPH:BIOPOR) har i dag besluttet at udstede i alt 5.000.000 warrants til et medlem af Selskabets direktion. Hver warrant giver indehaveren ret til at tegne én aktie i BioPorto til en udnyttelseskurs på 1,28 kr. pr. aktie, svarende til lukkekursen på Nasdaq Copenhagen i dag. Warrants udstedes i henhold til § 18 a i S...

September 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch